Top

Osteoporosis International

Published in:

Open Access 01-08-2009 | Original Article

Effect of daily oral minodronate on vertebral fractures in Japanese postmenopausal women with established osteoporosis: a randomized placebo-controlled double-blind study

Authors: T. Matsumoto, H. Hagino, M. Shiraki, M. Fukunaga, T. Nakano, K. Takaoka, H. Morii, Y. Ohashi, T. Nakamura

Published in: Osteoporosis International | Issue 8/2009

Abstract

Summary

A randomized placebo-controlled trial was conducted to examine the effect of daily oral 1 mg minodronate on vertebral fractures in 704 postmenopausal women with established osteoporosis for 24 months. Minodronate treatment reduced vertebral fractures by 59% without serious adverse events. Minodronate is a safe and effective bisphosphonate for osteoporosis treatment.

Introduction

Minodronate increases bone mineral density (BMD) in postmenopausal osteoporotic patients. However, its efficacy in reducing osteoporotic fractures has not been tested.

Methods

To examine anti-fracture efficacy and safety of daily oral minodronate in postmenopausal women with established osteoporosis, a randomized, double-blind, placebo-controlled trial was conducted in 704 postmenopausal women (55 to 80 years) with one to five vertebral fractures and low BMD. Subjects were randomly assigned to receive daily oral 1 mg minodronate (n = 359) or placebo (n = 345) for 24 months, with daily supplements of 600 mg calcium and 200 IU vitamin D₃.

Results

Daily 1 mg minodronate for 24 months reduced the risk of vertebral fractures by 59% (95% CI, 36.6–73.3%). Furthermore, when fractures during the first 6 months were eliminated, the risk of vertebral fractures from 6 to 24 months was reduced by 74% in minodronate-treated group. Minodronate treatment also reduced height loss. Bone turnover markers were suppressed by about 50% after 6 months of minodronate treatment and remained suppressed thereafter. The overall safety profile including gastrointestinal safety was similar between the two groups.

Conclusions

Daily oral minodronate is safe, well-tolerated, and is effective in reducing vertebral fracture risk in postmenopausal women with established osteoporosis.

Ettinger B, Black DM, Nevitt MC et al (1992) Contribution of vertebral deformities to chronic back pain and disability. The study of osteoporotic fractures research group. J Bone Miner Res 7:449–456PubMed

Ross PD, Fujiwara S, Huang C et al (1995) Vertebral fracture prevalence in women in Hiroshima compared to Caucasians or Japanese in the US. Int J Epidemiol 24:1171–1177PubMedCrossRef

Lindsay R, Silverman SL, Cooper C et al (2001) Risk of new vertebral fracture in the year following a fracture. JAMA 285:320–323PubMedCrossRef

Cauley JA, Thompson DE, Ensrud KC et al (2000) Risk of mortality following clinical fractures. Osteoporos Int 11:556–561PubMedCrossRef

Ensrud KE, Thompson DE, Cauley JA et al (2000) Prevalent vertebral deformities predict mortality and hospitalization in older women with low bone mass. Fracture intervention trial research group. J Am Geriatr Soc 48:241–249PubMed

Yoshida Y, Moriya A, Kitamura K et al (1998) Responses of trabecular and cortical bone turnover and bone mass and strength to bisphosphonate YH529 in ovariohysterectomized beagles with calcium restriction. J Bone Miner Res 13:1011–1022PubMedCrossRef

Dunford JE, Thompson K, Coxon FP et al (2001) Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 296:235–242PubMed

Morii H, Nishizawa Y, Taketani Y et al (2002) A randomized controlled trial with ONO-5920 (Minodronate/YM529) in Japanese patients with postmenopausal osteoporosis. J Bone Miner Res 17(Suppl):S471

Orimo H, Hayashi Y, Fukunaga M et al (2001) Diagnostic criteria of primary osteoporosis: year 2000 revision. Osteoporosis diagnostic criteria review committee: Japanese society for bone mineral research. J Bone Miner Metab 19:331–937PubMedCrossRef

10.

Orimo H, Sugioka Y, Fukunaga M et al (1996) Diagnostic criteria of primary osteoporosis (1996 version). Osteoporosis diagnostic criteria review committee: Japanese society for bone and mineral research. Osteoporosis Jpn 4:643–653

11.

Harris ST, Watts NB, Genant HK et al (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. A randomized controlled trial. JAMA 282:1344–1352PubMedCrossRef

12.

Genant HK, Wu CY, Van Kuijk C et al (1993) Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8:1137–1148PubMedCrossRef

13.

Wu CY, Li J, Jergas M et al (1995) Comparison of semiquantitative and quantitative techniques for the assessment of prevalent and incident vertebral fractures. Osteoporos Int 5:354–370PubMedCrossRef

14.

James IT, Perrett D, Thompson PW (1990) Rapid assay for hard tissue collagen cross-links using isocratic ion-pair reversed-phase liquid chromatography. J Chromatogr 525:43–57PubMedCrossRef

15.

Chesnut CH, Skag A, Christiansen C et al (2004) Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19:1241–1249CrossRef

16.

Black DM, Delmas PD, Eastell R et al (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809–1822PubMedCrossRef

Title: Effect of daily oral minodronate on vertebral fractures in Japanese postmenopausal women with established osteoporosis: a randomized placebo-controlled double-blind study
Authors: T. Matsumoto
H. Hagino
M. Shiraki
M. Fukunaga
T. Nakano
K. Takaoka
H. Morii
Y. Ohashi
T. Nakamura
Publication date: 01-08-2009
Publisher: Springer-Verlag
Published in: Osteoporosis International / Issue 8/2009
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-008-0816-7

At a glance: The STEP trials

Springer Medicine

Effect of daily oral minodronate on vertebral fractures in Japanese postmenopausal women with established osteoporosis: a randomized placebo-controlled double-blind study

Abstract

Summary

Introduction

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Summary

Introduction

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 8/2009

Tribute to Pierre D. Delmas

A reference database for the Stratec XCT-2000 peripheral quantitative computed tomography (pQCT) scanner in healthy children and young adults aged 6–19 years

Targeted exercises against hip fragility

Bone microdamage: a clinical perspective

Spine radiographs to improve the identification of women at high risk for fractures

Thinking inside and outside the envelopes of bone